Navigation Links
OncoSec Closes $7.75 Million Public Offering
Date:3/28/2012

her treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, without limitation, the satisfaction of the closing conditions and our dependence on the investors' commitments to fulfill their obligations in connection with our private placement financing, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks an
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. OncoSec to Present at 10th Annual BioPartnering North America
2. OncoSec Medical Reports Third Quarter 2011 Financial Results
3. OncoSec Announces Clinical Leadership Appointments
4. OncoSec Announces Leadership Team Appointments
5. OncoSec Medical Featured in Medical Device Daily
6. OncoSec Medical Appoints Punit Dhillon as President and CEO
7. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
8. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
9. Karyopharm Therapeutics Closes $10 Million Series A2 Financing to Expand Planned Phase 1 Program of Oral Selective Inhibitors of Nuclear Export (SINE) for Cancer
10. VisionGate Closes $2 Million Financing and Announces Collaboration to Evaluate Its 3D Cell Imaging Platform for Early Lung Cancer Detection
11. Spinifex Closes AU$18.25M(~US$19M) Expanded Series B Round
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... rather than electricity, to move data would consume ... a growing concern as chips, transistor counts rise. ... circuits light emitters, modulators, and detectors ... light source for optical chips is molybdenum disulfide ... as a single, atom-thick layer. Other experimental on-chip ...
(Date:9/19/2014)... , Sept. 19, 2014 Pfenex Inc. ... the development of high-value and difficult to manufacture proteins ... presenting at the 21 st Annual NewsMakers in ... . Bertrand Liang , chief executive officer ... development programs and business strategy on Friday, September 26, ...
(Date:9/19/2014)... , September 19, 2014 ... 53rd European Society for Paediatric Endocrinology (ESPE) Meeting  ... science and medical research in the field of growth  ... KGaA, Darmstadt, Germany , today announced ... (GGI) for 2014. The awards were announced during a ...
(Date:9/18/2014)... Sept. 18, 2014 /PRNewswire-iReach/ -- DeepResearchReports.com adds "2014 ... Acid Industry" and "2014 Deep Research Report on ... its research database. Photo - ... Report on Global and China Acetic Acid Industry" ... China and Global Acetic ...
Breaking Biology Technology:Toward optical chips 2Toward optical chips 3Pfenex to Present at Upcoming Industry Conference on September 26 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 2Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 3Acetic Acid Market & Sodium Stannate Industry (China, Global) Research Report 4
... are subject to a wide array of federal government ... report published by the nonprofit American Botanical Council (ABC). ... dietary supplements that are granted to the U.S. Food ... (FTC), as well as other government agencies. ...
... TRIANGLE PARK, N.C., Feb. 6, 2012  Chimerix, Inc., ... announced positive results from CMX001 Study 201, a ... of cytomegalovirus (CMV) disease in hematopoietic stem cell ... Lipid-Antiviral-Conjugate completing Phase 2 clinical development for the ...
... Inc., a critical care company focused on developing and commercializing ... ill patients in the hospital and ICU settings, today announced ... the 14th Annual BIO CEO & Investor Conference.  Mr. Tasse,s ... 3:30 p.m. EST in the Park South of the Waldorf ...
Cached Biology Technology:Dietary Supplements Extensively Regulated, Say Authors of New Article 2Dietary Supplements Extensively Regulated, Say Authors of New Article 3Dietary Supplements Extensively Regulated, Say Authors of New Article 4Dietary Supplements Extensively Regulated, Say Authors of New Article 5Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 2Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 3Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 4Chimerix Antiviral Compound, CMX001, Meets CMV Phase 2 Primary Endpoint in Allogeneic Hematopoietic Stem Cell Transplant Recipients 5Ikaria® to Present at 14th Annual BIO CEO & Investor Conference 2
(Date:9/18/2014)... The ability to acquire and creatively manipulate spoken language ... over the past 6 million years of human evolution ... is the best candidate gene we now have," says ... LMU. In his efforts to understand the molecular biological ... step forward. The results of his latest study, undertaken ...
(Date:9/18/2014)... cheerful, happy-go-lucky characters, so you might expect that most ... In fact some dogs are distinctly more pessimistic than ... , "This research is exciting because it measures positive ... It offers researchers and dog owners an insight into ... Dr Melissa Starling, from the Faculty of Veterinary Science. ...
(Date:9/18/2014)... is it that when people are too stressed they ... from the Brain Mind Institute (BMI) at EPFL have ... relationship between chronic stress and the loss of social ... enzyme attacks a synaptic regulatory molecule in the brain. ... Nature Communications . , Carmen Sandi,s team went ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Dogs can be pessimists too 2Dogs can be pessimists too 3How stress tears us apart 2
... new species of dinosaur unearthed in Mexico is giving scientists ... according to an international research team led by scientists from ... Utah. To date, the dinosaur record from Mexico has ... Museum of Natural History, Utahs designated natural history museum. ...
... U.S. Department of Homeland,Security (DHS) announced today ... international visitors arriving at San Francisco,International Airport ... the,department,s upgrade from two- to 10-fingerprint collection ... more accurately and,efficiently establishing and verifying visitors, ...
... at the Moores Cancer Center at University of California, San ... who were treated with a gene therapy protocol began making ... will be published on line the week of February 11-15 ... Academy of Science. Researchers led by Thomas J. Kipps, ...
Cached Biology News:New dinosaur from Mexico offers insights into ancient life on West America 2New dinosaur from Mexico offers insights into ancient life on West America 3New dinosaur from Mexico offers insights into ancient life on West America 4New dinosaur from Mexico offers insights into ancient life on West America 5New dinosaur from Mexico offers insights into ancient life on West America 6DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport 2Gene therapy protocol at UCSD activates immune system in patients with leukemia 2
... of a class of proteins who function to ... S plays an integral role in proofreading the ... excision repair and in preventing chromosomal recombination between ... DNA specifically at base pair mismatches and small ...
TGase3 (S-20)...
... the industrys first PCI Express image acquisition ... acquire images at the highest speeds, resolutions, ... cameras to perform demanding imaging applications such ... analysis, and advanced motion tracking. In ...
Simple operation and an easy-to-read LCD display characterize our Classic Light balances. * Taring range 0...1510 g...
Biology Products: